"The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) in the strengths of Palbociclib capsules, 75 mg, 100 mg, and 125 mg," Alembic Pharmaceuticals said in a regulatory filing.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lbjyzO
via IFTTT
0 comments:
Post a Comment